Introduction
80% of the couples achieve conception within 1 year of having regular unprotected intercourse with adequate frequency (4-5times/ week). According to the Indian Society of Assisted Reproduction, infertility currently affects about 10-14 percent of the Indian population, in which male is directly responsible in about 30-40% and female in about 40-55% and both are responsible in 10% cases. PCOS is one of the most common cause of infertility affecting 6% women within reproductive age & still increasing due to lifestyle changes and other familial factors. 1 In India the prevalence is 3.7-22.5%. 2 It is characterised by a combination of hyperandrogenism (either Clinical or Biochemical), chronic anovulation & polycystic ovaries. It is frequently associated with insulin resistance & obesity. 3 It belongs to group 2 ovulatory disorder (hypothalamic pituitary dysfunction) according to WHO classification. PCOS diagnosis is routinely done clinically following Rotterdam's criteria. Ovulation induction is the mainstay of treatment for infertile couple after primary evaluation and failure of medical method seeks surgical intervention.
Clomiphene citrate (CC) is till date a first line ovulation induction agent. It is long-standing, standard drug for ovulation induction. 4, 5 However, clomiphene has certain well-defined disadvantages. Treatment with CC is associated with discrepancy in ovulation and pregnancy rates (60-85%; 10-20%). Miscarriage rate is higher than general population, 6,7 and 20-25% PCOS women are resistant to clomiphene. 8, 9 Anti-estrogenic effect of CC leads to prolonged depletion of estrogens receptors, https://doi.org/10.18231/j.ijogr.2020.003 2394-2746/© 2020 Innovative Publication, All rights reserved. 12 adversely affecting endometrial growth and development as well as quantity and quality of cervical mucus. So, though ovulation rate is really good with this drug but final outcome in respect to a successful pregnancy is still a doubt. Letrozole is an orally-active aromatase inhibitor, with good potential for ovulation induction. It has been in use for few years now, and numbers of researchers have studied this molecule as an option for ovulation induction. 8, 10 Its mode of action is by reducing estrogen production by blocking androgens to estrogens conversion. Additionally, it has no adverse effect on endometrium and cervical mucus. In India, letrozole was approved for ovulation induction from 2006 to 2011 by the Drug controller general of India (DCGI). Letrozole has been shown to have good ovulation rate in CC-resistant PCOS women. 11 Indian PCOS women have high prevalence of insulin resistance 12 and thus are likely to have high CC resistance. Letrozole could prove to be a good alternative for ovulation induction in such women.
Materials and Methods
This clinical trial was carried out at OBG OPD SSIMS & RC from 1 st June to 31 st December 2018. Total 50 patients of PCOS were included in the study. Diagnosis of PCOS was made on Rotterdam criteria. Exclusion criteria were patients with renal, liver or thyroid diseases. In this trial 50 infertile patients with PCOS received either 100 mg CC (n=25) or 2.5 mg Letrozole (n=25) daily since day 2-6 or day 3-7 of cycle. Serial follicular measurements were done by same observer from day 9 onwards and Human chorionic gonadotrophin was administered at a dose of 5,000 IU when at least 1 mature follicle (18-22 mm) was detected. Timed intercourse was advised to the patients after 24-36 hrs of hCG. Then the number of follicles, endometrial thickness, ovulation rate & pregnancy rate were measured in both groups. In relation to side effects-in Letrozole group only 4% patients had OHSS whereas Clomiphene Citrate group had 12%. Similarly, 40% of patients receiving Clomiphene Citrate had multiple pregnancy, whereas in Letrozole group it was nil.
Results
Total 50 patients with infertility due to PCOS were included in the study. There were 25 patients in the CC group and remaining 25 patients were in the letrozole group. Patient Characteristics like age, duration of infertility, BMI, presenting signs and symptoms were kept similar in both groups, which is depicted in Table 1 below.
In Table 2 , it shows 84% patients ovulated in first cycle of treatment in group 1, whereas in group 2 it was 92%.
Monofollicular development is statistically significant in group 2 (letrozole group) as compared to group 1 (Clomiphene citrate group), i.e. 61.9% in group 1 and 86.9% in group 2.
This study shows that Multifollicular development was greater in patients who received Clomiphene citrate (38.1%) as compared to those who received Letrozole (13.1%).
Endometrial response was statistically significant in Letrozole group (group 2) i.e. 9.18 + 1.49mm, as compared to Clomiphene group (group 1) i.e. 7.86 + 1.25mm.
This study also showed that the rate of OHSS was higher in patients who received Clomiphene citrate (group 1) i.e. 12%, as compared to patients who received Letrozole (group 2) i.e. 4%. Table 3 depicts the outcome of treatment observed in our study, where ovulation rate was higher in group 2(92%) as compared to group 1(84%). Similarly the pregnancy rate was also higher in group 2(36%) as compared to group 1(20%).
It was observed that rate of multiple pregnancy was higher in Group 1 i.e. 40%, whereas none of the subjects in Group 2 developed multiple pregnancies.
Discussion
Since 1960, Clomiphene Citrate was considered to be the sole first line ovulation induction agent. However, clomiphene resistance (15-20%), endometrial thinning, and poor cervical mucus (15-50% of cases) makes it ineffective in many situations. Letrozole, which is an aromatase inhibitor, has been explored as a good alternative by many researchers, but the evidence about its efficacy as compared to clomiphene is conflicting.
Clomiphene citrate (CC) is a non-steroidal tri-phenyl ethylene derivative.
It has both estrogen agonist & antagonist properties, depending on prevailing levels of endogenous estrogen. CC is a racemic mixture of 2 distinct stereo-isomers, enclomiphene (62%) and zuclomiphene (38%). Because of its structural similarity to estrogen, CC probably induces ovulation primarily through the effects on hypothalamic GnRH pulse generator. During CC treatment, Levels of LH & FSH rise then fall again after typical 5 day course of therapy. In normal cycling women, CC increases GnRH pulse frequency. In anovulatory women with PCOS, in whom GnRH pulse frequency is already very high, CC increases pulse amplitude but not the frequency. It can also be used in males with oligospermia.
Clomiphene Resistance
It is defined as absent of ovulation (absence of follicular development on TVS with concomitant failure of E2 levels to raise) after treatment with CC (100mg for 5 days in 3 cycles). It is seen in 20-25% of the cases.
Known side effects are vasomotor flushes, breast tenderness, pelvic discomfort, nausea, visual disturbances, rarely OHSS (Ovarian hyper-stimulation syndrome).
Letrozole is third generation aromatase inhibitor used for treatment of breast cancer in post menopausal women for Aromatase inhibitors release the HPO axis from the estrogenic negative feedback, increase gonadotrophin secretion, and stimulate ovarian follicular development. Locally in the ovary they increase the follicular sensitivity to FSH. Advantages of letrozole over CC are: 1) Rapid elimination from the body (half life-45 hrs), 2) no adverse anti-estrogenic effects on endometrium or cervical mucus, 3) absence of estrogen receptor depletion and, 4) limited number of mature follicles(decrease incidence of OHSS & multiple pregnancy).
In our study, CC group shows statistically significant multi-follicular development (CC 38.1%, Let 13.1%). This is expected and corroborated by number of studies. Letrozole resulted in mono-folliculogenesis in 86.9% of cases, which is optimal for ovulation induction in PCOS women. However, where multiple follicular development is needed, letrozole may be inadequate.
In our study, the mean endometrial thickness was slightly higher in letrozole group, 9.18 + 1.49 compared to CC 7.86±1.25. In a recent study by Banerjee et al 147 Indian women with PCOS were compared between letrozole (2.5 mg) Vs. clomiphene (100 mg). Mean endometrial development was 8.72±11.41 mm in letrozole and 8.78±1.16mm in CC group (P = 0.004). Mitwally and Casper found letrozole associated with greater endometrial thickness. 13 Badawy et al. 14 in their study of 438 patients with 1063 cycles, one of the largest studies comparing CC and letrozole, reported statistically significantly higher endometrial thickness in CC group (9.2±0.7) vs. letrozole (8.1±0.2,P = 0.021). Few studies have shown no significant difference between the two groups with regard to effect on endometrium. 15, 16 Pregnancy rate per cycle was astonishingly high with letrozole in our study (36.0%) Vs. 14, [17] [18] [19] The ovulation rate for letrozole in comparison with clomiphene did not differ significantly, being 84% with CC vs 92% with letrozole.
In a meta-analysis by He and Jiang, 20 the clinical efficacy of letrozole was compared with clomiphene for ovulation induction in PCOS women. This is one of the largest meta-analysis of the subject published. Six RCTs involving 841 patients were analyzed. There were no significant differences in pregnancy rate, abortion rate, and multiple pregnancy rate between the two groups. The evidence from ovulation rate was not enough to support either of the drugs.
Conclusion
Our study showed statistically significantly higher monofollicular development and pregnancy rates when letrozole was used as ovulation induction drug in infertile PCOS women. Whereas, though CC group showed good ovulation rate but final outcome was poor which can be due to antiestrogenic effect resulting poor endometrial response and negative effect on cervical mucus.
However there is need for larger well designed randomized trials to generate robust data in order to establish the true potential of letrozole.
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